Search Results - "Arena, Sabrina"

Adaptive mutability of colorectal cancers in response to targeted therapies by Russo, Mariangela, Crisafulli, Giovanni, Sogari, Alberto, Reilly, Nicole M, Arena, Sabrina, Lamba, Simona, Bartolini, Alice, Amodio, Vito, Magrì, Alessandro, Novara, Luca, Sarotto, Ivana, Nagel, Zachary D, Piett, Cortt G, Amatu, Alessio, Sartore-Bianchi, Andrea, Siena, Salvatore, Bertotti, Andrea, Trusolino, Livio, Corigliano, Mattia, Gherardi, Marco, Lagomarsino, Marco Cosentino, Di Nicolantonio, Federica, Bardelli, Alberto

“…The emergence of drug resistance limits the efficacy of targeted therapies in human tumors. The prevalent view is that resistance is a fait accompli: when…”
Get full text

Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges by Durinikova, Erika, Buzo, Kristi, Arena, Sabrina

“…Abstract Colorectal cancer (CRC) is a complex and heterogeneous disease, characterized by dismal prognosis and low survival rate in the advanced (metastatic)…”
Get full text

Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients by De Lazzari, Giada, Opattova, Alena, Arena, Sabrina

“…Over the last few decades, the incidence of urogenital cancers has exhibited diverse trends influenced by screening programs and geographical variations. Among…”
Get full text

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer by Di Nicolantonio, Federica, Martini, Miriam, Molinari, Francesca, Sartore-Bianchi, Andrea, Arena, Sabrina, Saletti, Piercarlo, De Dosso, Sara, Mazzucchelli, Luca, Frattini, Milo, Siena, Salvatore, Bardelli, Alberto

“…PURPOSE Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately…”
Get full text

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer by Arena, Sabrina, Bellosillo, Beatriz, Siravegna, Giulia, Martínez, Alejandro, Cañadas, Israel, Lazzari, Luca, Ferruz, Noelia, Russo, Mariangela, Misale, Sandra, González, Iria, Iglesias, Mar, Gavilan, Elena, Corti, Giorgio, Hobor, Sebastijan, Crisafulli, Giovanni, Salido, Marta, Sánchez, Juan, Dalmases, Alba, Bellmunt, Joaquim, De Fabritiis, Gianni, Rovira, Ana, Di Nicolantonio, Federica, Albanell, Joan, Bardelli, Alberto, Montagut, Clara

“…Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design…”
Get full text

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer by Van Emburgh, Beth O., Arena, Sabrina, Siravegna, Giulia, Lazzari, Luca, Crisafulli, Giovanni, Corti, Giorgio, Mussolin, Benedetta, Baldi, Federica, Buscarino, Michela, Bartolini, Alice, Valtorta, Emanuele, Vidal, Joana, Bellosillo, Beatriz, Germano, Giovanni, Pietrantonio, Filippo, Ponzetti, Agostino, Albanell, Joan, Siena, Salvatore, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Montagut, Clara, Bardelli, Alberto

“…Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers…”
Get full text

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer by Misale, Sandra, Arena, Sabrina, Lamba, Simona, Siravegna, Giulia, Lallo, Alice, Hobor, Sebastijan, Russo, Mariangela, Buscarino, Michela, Lazzari, Luca, Sartore-Bianchi, Andrea, Bencardino, Katia, Amatu, Alessio, Lauricella, Calogero, Valtorta, Emanuele, Siena, Salvatore, Di Nicolantonio, Federica, Bardelli, Alberto

“…Colorectal cancers (CRCs) that are sensitive to the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab almost always develop…”
Get more information

Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy by Picco, Gabriele, Cattaneo, Chiara M, van Vliet, Esmée J, Crisafulli, Giovanni, Rospo, Giuseppe, Consonni, Sarah, Vieira, Sara F, Rodríguez, Iñigo Sánchez, Cancelliere, Carlotta, Banerjee, Ruby, Schipper, Luuk J, Oddo, Daniele, Dijkstra, Krijn K, Cinatl, Jindrich, Michaelis, Martin, Yang, Fengtang, Di Nicolantonio, Federica, Sartore-Bianchi, Andrea, Siena, Salvatore, Arena, Sabrina, Voest, Emile E, Bardelli, Alberto, Garnett, Mathew J

“…Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H)…”
Get more information

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer by Oddo, Daniele, Sennott, Erin M, Barault, Ludovic, Valtorta, Emanuele, Arena, Sabrina, Cassingena, Andrea, Filiciotto, Genny, Marzolla, Giulia, Elez, Elena, van Geel, Robin M J M, Bartolini, Alice, Crisafulli, Giovanni, Boscaro, Valentina, Godfrey, Jason T, Buscarino, Michela, Cancelliere, Carlotta, Linnebacher, Michael, Corti, Giorgio, Truini, Mauro, Siravegna, Giulia, Grasselli, Julieta, Gallicchio, Margherita, Bernards, René, Schellens, Jan H M, Tabernero, Josep, Engelman, Jeffrey A, Sartore-Bianchi, Andrea, Bardelli, Alberto, Siena, Salvatore, Corcoran, Ryan B, Di Nicolantonio, Federica

“…Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF-mutant colorectal cancer, emergence of acquired…”
Get full text

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations by Arena, Sabrina, Siravegna, Giulia, Mussolin, Benedetta, Kearns, Jeffrey D, Wolf, Beni B, Misale, Sandra, Lazzari, Luca, Bertotti, Andrea, Trusolino, Livio, Adjei, Alex A, Montagut, Clara, Di Nicolantonio, Federica, Nering, Rachel, Bardelli, Alberto

“…The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab are used to treat RAS wild-type colorectal cancers (CRCs), but their…”
Get more information

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance by Ali, Moiez, Kaltenbrun, Erin, Anderson, Gray R., Stephens, Sarah Jo, Arena, Sabrina, Bardelli, Alberto, Counter, Christopher M., Wood, Kris C.

“…KRAS mutations drive resistance to targeted therapies, including EGFR inhibitors in colorectal cancer (CRC). Through genetic screens, we unexpectedly find that…”
Get full text

Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer by Agostini, Antonio, Guerriero, Ilaria, Piro, Geny, Quero, Giuseppe, Roberto, Luca, Esposito, Annachiara, Caggiano, Alessia, Priori, Lorenzo, Scaglione, Giulia, De Sanctis, Francesco, Sistigu, Antonella, Musella, Martina, Larghi, Alberto, Rizzatti, Gianenrico, Lucchetti, Donatella, Alfieri, Sergio, Sgambato, Alessandro, Bria, Emilio, Bizzozero, Laura, Arena, Sabrina, Ugel, Stefano, Corbo, Vincenzo, Tortora, Giampaolo, Carbone, Carmine

“…Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. This is due to its aggressive course, late diagnosis and its intrinsic drugs resistance. The…”
Get full text

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells by Konishi, Hiroyuki, Mohseni, Morassa, Tamaki, Akina, Garay, Joseph P, Croessmann, Sarah, Karnan, Sivasundaram, Ota, Akinobu, Wong, Hong Yuen, Konishi, Yuko, Karakas, Bedri, Tahir, Khola, Abukhdeir, Abde M, Gustin, John P, Cidado, Justin, Wang, Grace M, Cosgrove, David, Cochran, Rory, Jelovac, Danijela, Higgins, Michaela J, Arena, Sabrina, Hawkins, Lauren, Lauring, Josh, Gross, Amy L, Heaphy, Christopher M, Hosokawa, Yositaka, Gabrielson, Edward, Meeker, Alan K, Visvanathan, Kala, Argani, Pedram, Bachman, Kurtis E, Park, Ben Ho

“…Biallelic inactivation of cancer susceptibility gene BRCA1 leads to breast and ovarian carcinogenesis. Paradoxically, BRCA1 deficiency in mice results in early…”
Get full text

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT) by Falcinelli, Marta, Dell’Omo, Giulia, Grassi, Elena, Mariella, Elisa, Leto, Simonetta Maria, Scardellato, Sharon, Lorenzato, Annalisa, Arena, Sabrina, Bertotti, Andrea, Trusolino, Livio, Bardelli, Alberto, d’Adda di Fagagna, Fabrizio

“…Telomere maintenance is necessary to maintain cancer cell unlimited viability. However, the mechanisms maintaining telomere length in colorectal cancer (CRC)…”
Get full text

Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer by Mariella, Elisa, Grasso, Gaia, Miotto, Martina, Buzo, Kristi, Reilly, Nicole Megan, Andrei, Pietro, Vitiello, Pietro Paolo, Crisafulli, Giovanni, Arena, Sabrina, Rospo, Giuseppe, Corti, Giorgio, Lorenzato, Annalisa, Cancelliere, Carlotta, Barault, Ludovic, Gionfriddo, Giulia, Linnebacher, Michael, Russo, Mariangela, Di Nicolantonio, Federica, Bardelli, Alberto

“…Multiple strategies are continuously being explored to expand the drug target repertoire in solid tumors. We devised a novel computational workflow for…”
Get full text

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies by Russo, Mariangela, Lamba, Simona, Lorenzato, Annalisa, Sogari, Alberto, Corti, Giorgio, Rospo, Giuseppe, Mussolin, Benedetta, Montone, Monica, Lazzari, Luca, Arena, Sabrina, Oddo, Daniele, Linnebacher, Michael, Sartore-Bianchi, Andrea, Pietrantonio, Filippo, Siena, Salvatore, Di Nicolantonio, Federica, Bardelli, Alberto

“…Attempts at eradicating metastatic cancers with targeted therapies are limited by the emergence of resistant subclones bearing heterogeneous (epi)genetic…”
Get full text

Expression and Functional Regulation of Myoglobin in Epithelial Cancers by Flonta, Simona Emilia, Arena, Sabrina, Pisacane, Alberto, Michieli, Paolo, Bardelli, Alberto

“…Myoglobin is a multifunctional heme protein that is thought to be expressed exclusively in myocytes. Its importance in both oxygen transport and free radical…”
Get full text

Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient by Torchiaro, Erica, Petti, Consalvo, Arena, Sabrina, Sassi, Francesco, Migliardi, Giorgia, Mellano, Alfredo, Porporato, Roberta, Basiricò, Marco, Gammaitoni, Loretta, Berrino, Enrico, Montone, Monica, Corti, Giorgio, Crisafulli, Giovanni, Marchiò, Caterina, Bardelli, Alberto, Medico, Enzo

“…High-grade mucinous colorectal cancer (HGM CRC) is particularly aggressive, prone to metastasis and treatment resistance, frequently accompanied by "signet…”
Get full text

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses by Di Nicolantonio, Federica, Arena, Sabrina, Gallicchio, Margherita, Zecchin, Davide, Martini, Miriam, Flonta, Simona Emilia, Stella, Giulia Maria, Lamba, Simona, Cancelliere, Carlotta, Russo, Mariangela, Geuna, Massimo, Appendino, Giovanni, Fantozzi, Roberto, Medico, Enzo, Bardelli, Alberto

“…Mutations in oncogenes and tumor suppressor genes are responsible for tumorigenesis and represent favored therapeutic targets in oncology. We exploited…”
Get full text

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition by Corti, Giorgio, Buzo, Kristi, Berrino, Enrico, Miotto, Martina, Aquilano, Maria Costanza, Lentini, Marilena, Bellomo, Sara Erika, Lorenzato, Annalisa, Bartolini, Alice, Mauri, Gianluca, Lazzari, Luca, Russo, Mariangela, Di Nicolantonio, Federica, Siena, Salvatore, Marsoni, Silvia, Marchiò, Caterina, Bardelli, Alberto, Arena, Sabrina

“…The synthetic lethal effect observed with the use of PARP inhibitors (PARPi) with tumors characterized by the loss of key players in the homologous…”
Get full text